Supplementary Materials

Supplementary Material for:

PGD2/DP2 receptor activation promotes severe viral bronchiolitis by suppressing IFN-λ production

Rhiannon B. Werder, Jason P. Lynch, Jennifer C. Simpson, Vivian Zhang, Nick H. Hodge, Matthew Poh, Elizabeth Forbes-Blom, Christina Kulis, Mark L. Smythe, John W. Upham, Kirsten Spann, Mark L. Everard, Simon Phipps*

*Corresponding author. Email: simon.phipps{at}

Published 9 May 2018, Sci. Transl. Med. 10, eaao0052 (2018)
DOI: 10.1126/scitranslmed.aao0052

This PDF file includes:

  • Materials and Methods
  • Fig. S1. h-PGDS expression.
  • Fig. S2. Effect of DP2 antagonism on antiviral immune cells.
  • Fig. S3. Effect of DP2 antagonism on type 2 inflammation.
  • Fig. S4. Effect of DP2 antagonism is not mediated by IL-13.
  • Fig. S5. Effect of DP1 and/or DP2 antagonism on antiviral cytokines.
  • Fig. S6. Effect of DP1 and/or DP2 agonism on antiviral cytokines.
  • Fig. S7. Effect of anti-TH2, DP1-alone or RSV+DP2 agonism in hAECs.
  • Fig. S8. A simplified schematic of the proposed mechanisms by which PGD2 suppresses or promotes antiviral immunity.
  • Table S1. hAEC donor characteristics.
  • Table S2. Oligonucleotide sequences used in this study.
  • Legend for table S3
  • References (6365)

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Table S3 (Microsoft Excel format). Primary data from this study.